| Attribute |
Value |
| Trial Name |
VALACY-PD (Valacyclovir for Parkinson's Disease) |
| Phase |
Phase 2 |
| Design |
Randomized, double-blind, placebo-controlled |
| Sample Size |
200 participants (100 per arm) |
| Duration |
12 months treatment, 3 months follow-up |
| Primary Endpoint |
Change in UPDRS-III score at 12 months |
| Secondary Endpoints |
HSV-1 antibody titers, inflammatory markers, non-motor symptoms |
| Sponsor |
Proposed academic consortium |
| ClinicalTrials.gov ID |
To be assigned |
¶ Rationale and Background
This clinical trial tests the Viral Trigger Hypothesis in Parkinson's Disease, which proposes that chronic or repeated reactivation of herpes simplex virus type 1 (HSV-1) contributes to neuroinflammation and dopaminergic neurodegeneration. The trial evaluates whether suppressing viral reactivation with valacyclovir can slow disease progression in early-stage PD patients.
¶ HSV-1 and Parkinson's Disease: Evidence Summary
Epidemiological and mechanistic studies support the link between HSV-1 and PD:
- Seroprevalence studies: HSV-1 seropositivity is associated with 2-3x increased PD risk in multiple cohorts
- Mechanistic links: HSV-1 can establish latency in trigeminal ganglion and reactivate under stress, triggering neuroinflammation
- Alpha-synuclein connection: HSV-1 infection promotes alpha-synuclein aggregation in cellular models
- Viral DNA in Lewy bodies: HSV-1 DNA has been detected in post-mortem brain tissue from PD patients
- Pro-drug of acyclovir: Valacyclovir has ~10x better oral bioavailability than acyclovir
- HSV-1 specificity: Effective against herpes simplex viruses
- Safety profile: Well-established safety in treating herpes infections
- Prior use in neurological conditions: Has been studied in herpes encephalitis and as adjuvant therapy
Primary Hypothesis: Chronic HSV-1 reactivation contributes to neuroinflammation and dopaminergic neurodegeneration in PD. Suppressing viral reactivation with valacyclovir will reduce inflammatory burden and slow motor progression.
Secondary Hypotheses:
- HSV-1 antibody avidity correlates with disease severity and progression rate
- Valacyclovir will reduce inflammatory markers (IL-6, TNF-α) compared to placebo
- Patients with evidence of prior HSV-1 exposure (seropositive) will derive greater treatment benefit
- Randomized, double-blind, placebo-controlled, parallel-group trial
- 1:1 allocation ratio
Inclusion Criteria:
- Clinical diagnosis of Parkinson's disease (UK Brain Bank criteria)
- Age 50-75 years
- Disease duration ≤3 years from diagnosis
- Hoehn-Yahr stage 1-2.5 (early disease)
- On stable antiparkinsonian medication for ≥4 weeks
- MMSE ≥26 (no significant cognitive impairment)
- Able to provide informed consent
Exclusion Criteria:
- Atypical parkinsonism (PSP, CBS, MSA)
- Significant cognitive impairment (MoCA <26)
- History of herpes encephalitis
- Current antiviral therapy use
- Immunosuppressive therapy (systemic steroids, DMARDs, biologics)
- Significant liver disease (ALT/AST >3x ULN)
- Significant renal disease (eGFR <60 mL/min)
- Pregnancy or breastfeeding
- Known hypersensitivity to valacyclovir or acyclovir
- Age (<65 vs ≥65 years)
- Disease duration (<18 months vs ≥18 months)
- Baseline UPDRS-III score
- Drug: Valacyclovir 1g oral tablet
- Dose: 1g twice daily (2g total daily)
- Duration: 12 months
- Rationale: Suppresses HSV-1 replication and reduces reactivation frequency
- Drug: Placebo (matched tablet appearance)
- Dose: Twice daily
- Duration: 12 months
- Participants continue standard antiparkinsonian therapy
- Avoid new HSV-1-active medications (acyclovir, famciclovir, penciclovir)
- Document all concomitant medications
| Endpoint |
Measurement |
Timepoints |
Justification |
| Motor progression |
UPDRS Part III (OFF medication) |
Baseline, 6, 12 months |
Standard PD progression measure |
| Viral reactivation burden |
HSV-1 IgG avidity index |
Baseline, 3, 6, 9, 12 months |
Measures viral activity |
| Systemic inflammation |
Serum IL-6, TNF-α |
Baseline, 6, 12 months |
Key inflammatory mediators |
| Endpoint |
Measurement |
Timepoints |
| Non-motor symptoms |
Non-Motor Symptoms Scale (NMSS) |
Baseline, 6, 12 months |
| Quality of life |
Parkinson's Disease Questionnaire-39 (PDQ-39) |
Baseline, 6, 12 months |
| Cognitive function |
Montreal Cognitive Assessment (MoCA) |
Baseline, 6, 12 months |
| Autonomic function |
SCOPA-AUT |
Baseline, 6, 12 months |
| Depression |
Geriatric Depression Scale (GDS-15) |
Baseline, 6, 12 months |
| Dopaminergic imaging |
DaTSPECT (optional subset, n=40) |
Baseline, 12 months |
| HSV-1 serostatus |
HSV-1 IgG, IgM |
Baseline, 12 months |
- Adverse events (AE) and serious adverse events (SAE)
- Liver function tests (ALT, AST, bilirubin)
- Renal function (creatinine, eGFR)
- Complete blood count
Assumptions:
- UPDRS-III progression in placebo group: 5 points/year (based on PD progression literature)
- Expected treatment effect: 40% reduction in progression (2 points)
- Standard deviation: 8 points
- Power: 80%
- Alpha: 0.05 (two-sided)
- 20% dropout rate
Calculation: n = 100 per arm = 200 total
- Mixed-effects model for repeated measures (MMRM)
- Treatment effect estimated as difference in least squares means
- Primary analysis: ITT population
- Per-protocol analysis
- Subgroup analyses by HSV-1 serostatus
- Correlation analyses: inflammatory markers vs. UPDRS progression
- Completer analysis
| Milestone |
Timeframe |
| Protocol development |
Months 1-3 |
| IRB approval |
Months 3-4 |
| Site preparation and recruitment start |
Months 4-5 |
| Enrollment completion |
Month 20 |
| Treatment completion |
Month 32 |
| Follow-up completion |
Month 35 |
| Database lock |
Month 36 |
| Primary results |
Month 38 |
- All adverse events recorded throughout study
- AE severity graded per CTCAE v5.0
- Causality assessment by investigator
-
3-fold increase in ALT/AST: Hold study drug, monitor
-
5-fold increase: Permanent discontinuation
- Serious adverse events: Report within 24 hours